Vandetanib (INN trade name Caprelsa) is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors mainly the vascular endothelial growth factor receptor (VEGFR) the epidermal growth factor receptor (EGFR) and the RET-tyrosine kinase. The drug was developed by AstraZeneca.
This page contains content from the copyrighted Wikipedia article "Vandetanib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
